Welcome to our dedicated page for Trinity Biotech news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech stock.
Trinity Biotech plc reports developments across its commercial-stage diagnostics and health technology business, including clinical laboratory products, point-of-care testing, diabetes management solutions, and wearable biosensor development. Its updates frequently cover the Premier Hb9210 HbA1c laboratory blood glucose monitoring platform, TrinScreen HIV testing, and the CGM+ continuous glucose monitoring program.
Company news also addresses specialty diagnostics initiatives such as EpiCapture prostate cancer testing and autoimmune biomarker work supported by its New York State Department of Health-certified reference laboratory. Other recurring topics include commercial operations in North America, manufacturing and cost-control actions under its Comprehensive Transformation Plan, ADS-based financing arrangements, trading updates, and Nasdaq listing-status notices.
Trinity Biotech (NASDAQ: TRIB) announced a strategic collaboration with Latch Medical to combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's hollow microneedle intradermal drug delivery technology, Pharma Latch™, to evaluate precision therapeutic solutions for diabetes, obesity and other metabolic conditions.
The partners plan to use real-time metabolic data from CGM+ to help guide and optimize injectable therapy delivery, aiming for more personalized, responsive treatment approaches. Trinity Biotech has also agreed in principle to make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors. The collaboration is intended to expand CGM+ beyond monitoring into an integrated metabolic health platform that combines continuous sensing, AI-driven insights and precision drug delivery, and builds on Trinity Biotech's recently announced positive CGM+ clinical trial data on nocturnal compression lows.
Trinity Biotech (Nasdaq: TRIB) plans to change its American depositary share (ADS) ratio from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares, effectively a 1‑for‑30 reverse ADS split for ADS holders.
The change is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement and to support investment from investors who prefer securities trading above $5.00. There is no change to the underlying Class A ordinary shares. The new ratio is expected to become effective at the start of Nasdaq trading on July 24, 2026.
ADS holders must mandatorily surrender every 30 existing ADSs to The Bank of New York Mellon to receive 1 new ADS. No fractional new ADSs will be issued; fractional entitlements will be aggregated, sold by the depositary, and net cash proceeds distributed to affected ADS holders. The ADSs will continue to trade on Nasdaq under the symbol TRIB, and the company expects the ADS price to increase proportionally, while giving no assurance that it will equal or exceed 30 times the prior price.
Trinity Biotech (Nasdaq: TRIB) reported new clinical data for its next-generation CGM+ wearable biosensor platform. Analysis of about 5,000 hours of pre-pivotal clinical wear data shows purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows.
The multi-sensor CGM+ system combines glucose with additional physiological signals and AI-driven analytics to add context beyond glucose-only CGM. According to Trinity Biotech, this supports differentiation in the approximately $15 billion global CGM market as CGM+ advances toward pivotal trial and regulatory submission.
Trinity Biotech (Nasdaq: TRIB) announced that its AI data center liquid cooling subsidiary Trinovium has secured Silver Membership in the Open Compute Project (OCP), providing direct engagement with leading hyperscale operators and technology firms.
According to Trinity Biotech, OCP participation should support product development, accreditation, hyperscale market access, and a capital-efficient entry into a liquid cooling market projected to grow from $4B in 2026 to $27B by 2033.
Trinity Biotech (Nasdaq: TRIB) announced on June 29, 2026 that it has given formal notice to terminate its Standby Equity Purchase Agreement (SEPA) with YA II PN, an affiliate of Yorkville Advisors Global, ending its related equity line of credit facility.
The company does not intend to use the SEPA further, and indicates that the termination aligns with its current financing strategy.
Trinity Biotech (NASDAQ:TRIB) launched Trinovium, a subsidiary focused on advanced liquid cooling fluids and intelligence systems for AI and high‑performance computing data centers.
Trinovium targets the data center liquid cooling market, projected to grow from $4 billion in 2026 to $27 billion by 2033 (31.5% CAGR), leveraging Trinity’s US/EU high‑purity fluid manufacturing and analytics. Initial products include a direct‑to‑chip coolant built around ultra‑high purity, corrosion protection, and healthcare‑grade consistency, plus a planned fluid health monitoring platform. Trinity continues to commercialize its FDA 510(k)‑cleared diabetes and hemoglobin analyzers, WHO‑prequalified HIV tests, and develop its CGM+ continuous glucose monitoring solution.
Trinity Biotech (Nasdaq: TRIB) received additional purchase orders for over 2 million TrinScreen HIV tests, scheduled for Q3 2026 fulfillment and expected to support 2026 revenue and profitability targets.
Q1 2026 revenue rose 43% to $10.8m, with gross margin improving from 25.2% to 35.4%. Net loss narrowed to $4.4m, and adjusted EBITDA was negative $1.1m. Rapid HIV sales reached $3.7m, including $2.3m from TrinScreen HIV, while haemoglobin product sales increased to $3.3m. Outsourced manufacturing scale-up for UniGold HIV and TrinScreen HIV is part of the Comprehensive Transformation Plan, aimed at further improving margins and cash generation.
Trinity Biotech (NASDAQ: TRIB) appointed Jerry Lydon as Head of North America Commercial Operations on May 1, 2026, to lead commercial execution and support revenue quality and profitability as the company shifts from transformation execution to extracting operating leverage.
Q4 2025 revenue was $11.1m; full‑year 2025 revenue was $43.8m. Gross margin improved ~400 bps year and quarter, adjusted EBITDA narrowed versus prior year, and one‑off IFRS charge of $10.0m affected net loss.
Trinity Biotech (Nasdaq: TRIB) reported successful clinical results for an enhanced EpiCapture™ urine-based prostate cancer test on March 23, 2026. The upgraded test uses machine learning with added patient features, including ethnicity, and showed an AUC of 85% in a study of ~750 diverse samples. Trinity plans to commercialize EpiCapture as a Laboratory Developed Test through its New York reference laboratory and will submit the data for peer-reviewed publication.
Trinity Biotech (Nasdaq: TRIB) entered a collaboration with the University at Buffalo to co-develop and commercialize a proprietary suite of biomarkers for earlier, more accurate detection of Sjögren’s Syndrome.
The agreement leverages biomarkers licensed to Trinity subsidiary IMMCO, UB CAT funding support, and Trinity’s NYSDOH-approved reference laboratory as the U.S. launch platform.